₹ 14823
₹522- ₹549
27
₹650
18
13 Dec 2024
Download17 Dec 2024
18 Dec 2024
Application Details
The Sai Life Sciences IPO is scheduled to open for subscription from December 11, 2024, to December 13, 2024. The IPO has a face value of ₹1 per share and a price band of ₹522 to ₹549 per share. Investors can apply in lots of 27 shares, with a minimum investment of ₹14,823 for one lot and a maximum investment of ₹1,92,699 for 13 lots (351 shares). The total issue size comprises 55,421,123 shares, aggregating up to ₹3,042.62 crore, which includes a Fresh Issue of 17,304,189 shares (₹950 crore) and an Offer for Sale of 38,116,934 shares (₹2,092.62 crore).
The IPO follows a Book Built Issue format, and the shares will be listed on both BSE and NSE. The reservation of shares allocates not more than 50% of the net offer to Qualified Institutional Buyers (QIBs), not less than 35% to retail investors, and not less than 15% to Non-Institutional Investors (NIIs or HNIs).
Key dates for the Sai Life Sciences IPO include the basis of allotment announcement on December 16, 2024, initiation of refunds and credit of shares to demat accounts on December 17, 2024, and the listing date on December 18, 2024.
About Sai Life Sciences Limited
Company Overview
Sai Life Sciences Limited, established in January 1999 as ‘Sai Dru Syn Laboratories Ltd,’ has undergone several name changes over the years, ultimately adopting its current name in May 2012. The company operates as a fully integrated, innovator-focused contract research, development, and manufacturing organization (CRDMO). It provides comprehensive services across the drug discovery, development, and manufacturing value chain for small-molecule new chemical entities (NCEs).
Key Milestones in Corporate Evolution
- 1999: Incorporated as Sai Dru Syn Laboratories Ltd in Hyderabad, Telangana.
- 2003: Renamed as Sai Life Sciences Ltd.
- 2006: Rebranded to Sai Advantium Pharma Ltd.
- 2012: Final name change back to Sai Life Sciences Ltd.
Core Services and Capabilities
Sai Life Sciences serves global pharmaceutical innovators and biotechnology firms, offering:
- Contract Research Organization (CRO) Services: Integrated discovery capabilities in biology, chemistry, and drug metabolism and pharmacokinetics (DMPK).
- Contract Development and Manufacturing Organization (CDMO) Services: Chemistry, manufacturing, and control (CMC) capabilities with a mix of commercial and under-development molecules.
The company’s infrastructure includes research laboratories in Watertown (Greater Boston, MA) and Manchester, UK, along with cost-efficient manufacturing facilities in India.
FAQ
IPO stands for "Initial Public Offering." It's the process through which a privately-held company becomes publicly traded by offering its shares to the general public and listing them on a stock exchange for trading. This allows the company to raise capital from investors and grants individuals and institutions the opportunity to invest in and own a portion of the company.
The life cycle of an IPO, or Initial Public Offering, begins with a company's decision to go public. It involves hiring underwriters, registering with regulatory authorities, determining the IPO price, marketing to investors, and the subscription period where investors place orders for shares. After allocation and listing, shares become publicly tradable, and the company enters the secondary market. Ongoing reporting and corporate governance are crucial as the company continues to operate as a publicly-traded entity. The IPO aims to raise capital for growth and provides investors with opportunities to trade shares in the company.
An IPO (Initial Public Offering) is when a private company goes public by selling shares to the public. Investors buy these shares, giving them ownership in the company. It's a way for companies to raise capital and expand. The process involves underwriters, regulatory filings, setting the IPO price, and marketing to investors. After the IPO, shares can be traded on a stock exchange. IPOs offer opportunities and risks, so investors should research and consider carefully.
"Upcoming IPOs" refers to initial public offerings that have been announced by private companies but have not yet occurred. These are companies that plan to go public in the near future by issuing shares to the public and listing them on a stock exchange. Investors often keep an eye on upcoming IPOs as they represent opportunities to invest in companies at their early stages of public trading, potentially capturing growth potential. These offerings are typically accompanied by significant media and investor attention as they approach their launch dates.